Actionable news
All posts from Actionable news
Actionable news in AZN: ASTRAZENECA PLC,

AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies

Two Phase 3 clinical trials, SIROCCO and CALIMA, assessing two dosing regimens of AstraZeneca's (NYSE:AZN) interleukin-5 inhibitor, benralizumab, as add-on therapy in patients with severe eosinophilic asthma met their primary and secondary endpoints. The data were presented at the European Respiratory Society International Congress in London. Detailed results were published today in The Lancet.

A total of 2,511 patients (1,205 in...